Preferred Label : Anti-B7-H4/MMAE ADC LNCB74;
NCIt synonyms : Antibody-drug Conjugate LNCB74; ADC LNCB74; Anti-B7-H4/MMAE Antibody-drug Conjugate LNCB74; Anti-B7-H4 ADC LNCB74;
NCIt definition : An antibody-drug conjugate (ADC) composed of a human immunoglobulin (Ig) G1 kappa
monoclonal antibody directed against the T-cell checkpoint ligand B7-H4 (V-set domain-containing
T-cell activation inhibitor 1; VTCN1; B7x; B7S1) conjugated, via a beta-glucuronidase-cleavable
linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule
disrupting agent, with potential antineoplastic and immunomodulating activities. Upon
administration of anti-B7-H4/MMAE ADC LNCB74, the anti-B7-H4 antibody targets and
binds to B7-H4 expressed on tumor cells. Upon binding and internalization, MMAE is
released upon cleavage by the cancer-associated lysosomal enzyme beta-glucuronidase.
MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest
and tumor cell apoptosis. This induces cell death in B7-H4-expressing cancer cells.
LNCB74 also induces a bystander effect, thereby further killing neighboring tumor
cells upon uptake of MMAE and induces an immune-mediated cell death. B7-H4, a member
of the B7 family of immune modulators, is upregulated in a variety of tumor cell types
and tumor-associated macrophages (TAMs) while minimally expressed in normal, healthy
tissues. It negatively regulates T-cell immune responses. LNCB74 contains a LALA-hG1
Fc region to minimize uptake and toxicity to immune cells, thereby further improving
the safety profile.;
Molecule name : LNCB 74; LNCB-74;
Origin ID : C213318;
concept_is_in_subset
- has_target
